We are live on
!
Find out more
AR
Advisory Research Portfolio holdings
AUM
$813M
1-Year Est. Return
36.71%
This Fund
S&P 500
This Quarter
Est. Return
+31.97%
1 Year Est. Return
+36.71%
3 Year Est. Return
+123.04%
5 Year Est. Return
+262.63%
10 Year Est. Return
+840.35%
AUM
$1.12B
AUM Growth
-$319M
(-22%)
Cap. Flow
-$563M
Cap. Flow
% of AUM
-50.08%
Top 10 Holdings %
Top 10 Hldgs %
21.26%
Holding
360
New
82
Increased
64
Reduced
136
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$15.3M |
| 2 |
Broadridge
BR
|
+$13.9M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$11.1M |
| 4 |
Dominion Energy
D
|
+$10.6M |
| 5 |
NextEra Energy
NEE
|
+$9.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CORE
Core Mark Holding Co., Inc.
CORE
|
+$34M |
| 2 |
Zurn Elkay Water Solutions
ZWS
|
+$26.8M |
| 3 |
Rio Tinto
RIO
|
+$26.3M |
| 4 |
TriMas Corp
TRS
|
+$23.6M |
| 5 |
Texas Instruments
TXN
|
+$23.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.12% |
| 2 | Technology | 14.48% |
| 3 | Financials | 14% |
| 4 | Industrials | 10.81% |
| 5 | Healthcare | 10.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
BioMarin Pharmaceuticals
BMRN
$11.5B
| $338K | 0.03% |
+2,743
| New | +$273K |
|
277
Itron
ITRI
$3.73B
| $329K | 0.03% |
4,972
-12,431
| -71% | -$792K |
|
278
Houlihan Lokey
HLI
$9.68B
| $322K | 0.03% |
5,786
-1,545
| -21% | -$90K |
|
279
Protolabs
PRLB
$1.86B
| $316K | 0.03% |
+2,814
| New | +$289K |
|
|
FITB
280
Fifth Third Bancorp
FITB
$52B
| $315K | 0.03% |
16,360
| – | – |
|
|
NVO
281
Novo Nordisk
NVO
$216B
| $315K | 0.03% |
9,630
-2,088
| -18% | -$66.6K |
|
282
Vanguard FTSE All-World ex-US ETF
VEU
$65.6B
| $311K | 0.03% |
6,535
| – | – |
|
283
Molina Healthcare
MOH
$10.3B
| $303K | 0.03% |
+1,704
| New | +$290K |
|
|
CERN
284
DELISTED
Cerner Corp
CERN
| $301K | 0.03% |
4,388
-18
| -0.4% | -$1.24K |
|
285
AllianceBernstein
AB
$3.47B
| $299K | 0.03% |
10,970
| – | – |
|
|
HZNP
286
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $295K | 0.03% |
5,309
-16,349
| -75% | -$699K |
|
|
DOCU
287
DocuSign
DOCU
$9.63B
| $282K | 0.03% |
1,639
-2,920
| -64% | -$368K |
|
|
AVLR
288
DELISTED
Avalara, Inc.
AVLR
| $279K | 0.02% |
2,096
-1,929
| -48% | -$190K |
|
289
Gladstone Investment Corp
GAIN
$635M
| $276K | 0.02% |
26,982
| – | – |
|
290
Stride
LRN
$3.69B
| $272K | 0.02% |
10,000
| – | – |
|
291
Alnylam Pharmaceuticals
ALNY
$36.3B
| $268K | 0.02% |
1,809
-632
| -26% | -$85.2K |
|
292
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.42B
| $258K | 0.02% |
+4,935
| New | +$249K |
|
293
Advanced Micro Devices
AMD
$851B
| $257K | 0.02% |
4,882
-1,293
| -21% | -$68.6K |
|
294
Incyte
INCY
$23.5B
| $253K | 0.02% |
+2,437
| New | +$235K |
|
295
Cognex
CGNX
$10.3B
| $248K | 0.02% |
+4,154
| New | +$226K |
|
296
Middleby
MIDD
$6.05B
| $248K | 0.02% |
+3,146
| New | +$204K |
|
297
SBA Communications
SBAC
$18.4B
| $246K | 0.02% |
827
-945
| -53% | -$279K |
|
298
ITT
ITT
$17.5B
| $239K | 0.02% |
+4,067
| New | +$216K |
|
299
W.W. Grainger
GWW
$65.3B
| $235K | 0.02% |
+747
| New | +$216K |
|
300
DexCom
DXCM
$27.6B
| $231K | 0.02% |
2,280
-5,084
| -69% | -$455K |
|
Similar funds
VFG
SLG
KCP
UAG
PS
CICI
RPAM
BBI
Advisory Research's Q2 2020 Portfolio in Review
As of Q2 2020, Advisory Research held 360 positions worth $1.12B, down 22% from $1.44B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Advisory Research withdrew a net $563M in Q2 2020, closing 54 positions and reducing 136 holdings. Its most notable exit was Chunghwa Telecom, an estimated $18.4M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 18% a quarter earlier, followed by Technology and Financials.
Against the trend, Advisory Research opened a new position in AbbVie worth $17M.
- Advisory Research's largest Q2 2020 buy was AbbVie: 173,370 shares worth $17M.
- Advisory Research added most to Motorola Solutions in Q2 2020, an estimated $5.55M increase.
- Advisory Research's biggest Q2 2020 reduction was Core Mark Holding Co., Inc., cutting an estimated $34M.
- Advisory Research fully exited Chunghwa Telecom in Q2 2020, selling an estimated $18.4M.
- Advisory Research's ten largest holdings make up 21% of its $1.12B portfolio in Q2 2020.
- Advisory Research opened 82 new positions and closed 54 in Q2 2020.
- Advisory Research's portfolio value fell 22% quarter-over-quarter to $1.12B.
Based on Advisory Research's 13F filing for Q2 2020, filed 13 Aug 2020.